DUANE MITCHELL

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers
    Chris A Learn
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:7306-15. 2006
  2. pmc Selective modification of antigen-specific T cells by RNA electroporation
    Duane A Mitchell
    Division of Neurosurgery, Department of Surgery, Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Hum Gene Ther 19:511-21. 2008
  3. pmc Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
    Duane A Mitchell
    Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 10:10-8. 2008
  4. pmc Immunotherapy of malignant brain tumors
    Duane A Mitchell
    Division of Neurosurgery, Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke, NC 27710, USA
    Immunol Rev 222:70-100. 2008
  5. pmc Toward effective immunotherapy for the treatment of malignant brain tumors
    Duane A Mitchell
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Neurotherapeutics 6:527-38. 2009
  6. ncbi request reprint Adoptive immunotherapy for malignant glioma
    Duane A Mitchell
    Department of Pathology and Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
    Cancer J 9:157-66. 2003
  7. ncbi request reprint Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
    Peter E Fecci
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:4294-305. 2006
  8. pmc EGFRvIII-targeted vaccination therapy of malignant glioma
    Bryan D Choi
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Brain Pathol 19:713-23. 2009
  9. doi request reprint Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines
    Robert J Schmittling
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol Methods 339:74-81. 2008
  10. pmc Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Semin Immunol 20:267-75. 2008

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers
    Chris A Learn
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:7306-15. 2006
    ..Analyses of T-cell mRNA expression profiles in glioblastoma multiforme has not been previously reported but may help to define and characterize the immunosuppressed phenotype in patients with this type of cancer...
  2. pmc Selective modification of antigen-specific T cells by RNA electroporation
    Duane A Mitchell
    Division of Neurosurgery, Department of Surgery, Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Hum Gene Ther 19:511-21. 2008
    ....
  3. pmc Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
    Duane A Mitchell
    Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 10:10-8. 2008
    ....
  4. pmc Immunotherapy of malignant brain tumors
    Duane A Mitchell
    Division of Neurosurgery, Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke, NC 27710, USA
    Immunol Rev 222:70-100. 2008
    ....
  5. pmc Toward effective immunotherapy for the treatment of malignant brain tumors
    Duane A Mitchell
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Neurotherapeutics 6:527-38. 2009
    ....
  6. ncbi request reprint Adoptive immunotherapy for malignant glioma
    Duane A Mitchell
    Department of Pathology and Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
    Cancer J 9:157-66. 2003
    ....
  7. ncbi request reprint Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
    Peter E Fecci
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:4294-305. 2006
    ..We therefore examined T(regs) in mice bearing malignant glioma and evaluated anti-CD25 as an immunotherapeutic adjunct...
  8. pmc EGFRvIII-targeted vaccination therapy of malignant glioma
    Bryan D Choi
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Brain Pathol 19:713-23. 2009
    ..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma...
  9. doi request reprint Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines
    Robert J Schmittling
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol Methods 339:74-81. 2008
    ..Using this assay, we found that significant levels of antibody for tumor-specific antigen EGFRvIII (>4 microg/mL) and KLH could be induced after vaccination with PEPvIII-KLH...
  10. pmc Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Semin Immunol 20:267-75. 2008
    ..The recurrence of EGFRvIII-negative tumors in our patients, however, highlights the need for targeting a broader repertoire of tumor-specific antigens...
  11. pmc Proteomic and immunologic analyses of brain tumor exosomes
    Michael W Graner
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    FASEB J 23:1541-57. 2009
    ..They can escape the blood-brain barrier, with potential systemic and distal signaling and immune consequences...
  12. ncbi request reprint The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors
    Peter E Fecci
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 64:161-76. 2003
    ..The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration...
  13. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  14. ncbi request reprint Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
    Peter E Fecci
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 66:3294-302. 2006
    ..These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system...
  15. pmc EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells
    Hidenobu Ochiai
    Department of Surgery Neurosurgery, Duke University Medical Center, Box 3050, Durham, NC, 27710, USA
    Cancer Immunol Immunother 57:115-21. 2008
    ..However, delayed and often dramatic antitumor responses seen in human studies with targeted toxins led us to hypothesize that immunologic responses may be a secondary mechanism that enhances the therapeutic efficacy of these novel drugs...
  16. ncbi request reprint Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function
    Peter E Fecci
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:2158-67. 2007
    ..Our murine glioma model recapitulates these findings. Here, we investigate the effects of systemic CTLA-4 blockade in this model...
  17. pmc Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity
    Chris A Learn
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States
    J Neuroimmunol 182:63-72. 2007
    ..Our findings support our hypothesis that glioma phenotype in vitro may be quite different in vivo and significantly altered by in situ growth factors and other invading cell populations...
  18. pmc An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Cancer Ther 8:2773-9. 2009
    ..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy...
  19. pmc Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Neuro Oncol 10:98-103. 2008
    ..In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery...

Research Grants4

  1. Reversal of CMV-specific immune deficits in patients with glioblastoma
    Duane Anthony Mitchell; Fiscal Year: 2010
    ..Improved therapy for cancer has significant potential to improve public health and quality of life for patients affected by malignant disease. ..
  2. Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide
    Duane Anthony Mitchell; Fiscal Year: 2010
    ..Improved therapy for cancer has significant potential to improve public health and quality of life for patients affected by malignant disease. ..